A- A A+

Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.

Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. 

J Infect Dis. 2022 Aug 26;226(3):431-440. doi: 10.1093/infdis/jiaa359. PMID: 32584386; PMCID: PMC9417129.

https://pubmed.ncbi.nlm.nih.gov/32584386

HIV? Hepatitis? Das CHECK ich! 

Modellprojekt zu Beratungen und Tests für Menschen, die Drogen gebrauchen, durchgeführt in niedrigschwelligen Einrichtungen der Drogenhilfe.

Abschlussbericht zu den Ergebnissen der Begleitevaluation

Herausgeberin: Bundeszentrale für gesundheitliche Aufklärung (BZgA), Juli 2020

https://www.liebesleben.de/fachkraefte/sexualaufklaerung-und-praeventionsarbeit/richtigen-zugang/

Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020. 

Thompson WW, Symum H, Sandul A, et al. 

MMWR Morb Mortal Wkly Rep 2022;71:1011-1017. doi.org/10.15585/mmwr.mm7132e1

https://www.cdc.gov/mmwr/volumes/71/wr/mm7132e1.htm

Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel. 

Fiore V, De Matteis G, Pontali E, De Vito A, Panese S, Geremia N, Maida I, Artioli S, Starnini G, Madeddu G, Babudieri S. 

Front Public Health. 2022 Oct 4;10:926414. doi: 10.3389/fpubh.2022.926414. PMID: 36268000; PMCID: PMC9577224.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577224/

Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). 

Palmateer N, Hamill V, Bergenstrom A, Bloomfield H, Gordon L, Stone J, Fraser H, Seyler T, Duan Y, Tran R, Trayner K, Biggam C, Smith S, Vickerman P, Hickman M, Hutchinson S. 

Int J Drug Policy. 2022 Nov;109:103872. doi: 10.1016/j.drugpo.2022.103872. Epub 2022 Oct 3. PMID: 36202039.

https://www.sciencedirect.com/science/article/pii/S0955395922002882

Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic. 

Losikoff P, Bosse JD, Martin SA, Wilson A, Chiodo LM. 

Front Psychiatry. 2022 Sep 14;13:932306. doi: 10.3389/fpsyt.2022.932306. PMID: 36186876; PMCID: PMC9515307.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515307/

Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study). 

Rolland B, Lions C, Di Beo V, Carrieri P, Authier N, Barré T, Delorme J, Mathurin P, Bailly F, Protopopescu C, Marcellin F. 

Harm Reduct J. 2022 Oct 27;19(1):119. doi: 10.1186/s12954-022-00702-9. PMID: 36303159; PMCID: PMC9615191.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615191/

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort). 

Barré T, Bourlière M, Ramier C, Carrat F, Di Beo V, Protopopescu C, Marcellin F, Bureau M, Cagnot C, Dorival C, Zoulim F, Zucman-Rossi J, Duclos-Vallée JC, Fontaine H, Carrieri P, The Anrs/Afef Hepather Study Group. 

J Clin Med. 2022 Oct 18;11(20):6135. doi: 10.3390/jcm11206135. PMID: 36294456; PMCID: PMC9605108.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605108/

Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. 

Barry, M.P., Austin, E.J., Bhatraju, E.P. et al.

Harm Reduct J 19, 121 (2022). doi.org/10.1186/s12954-022-00706-5

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00706-5

The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection. 

Miller-Archie SA, Walters SC, Bocour A, Moore MS, Wiewel E, Singh T, Lim S. 

J Infect Dis. 2022 Oct 7;226(Supplement_3):S363-S371. doi: 10.1093/infdis/jiac292. PMID: 36208165; PMCID: PMC9547527.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547527/

WHO-Empfehlungen: Hepatitis C ließe sich eliminieren

Dtsch Arztebl 2022; 119(38): A-1584 / B-1324

Lenzen-Schulte, Martina

https://www.aerzteblatt.de/archiv/227616

Neuer Check-up für die Leber: Warum Hepatitis-Tests so sinnvoll sind

Dtsch Arztebl 2022; 119(38): A-1590 / B-1322

Wolffram, Ingmar

https://www.aerzteblatt.de/archiv/227644

Impact of an Accelerated Pretreatment Evaluation on Linkage-to-Care for Hepatitis C-infected Persons Who Inject Drugs. 

Martel-Laferrière V, Brissette S, Wartelle-Bladou C, Juteau LC, Popa M, Goyer MÈ, Bruneau J. 

Subst Abuse. 2022 Aug 12;16:11782218221119068. doi: 10.1177/11782218221119068. PMID: 35990750; PMCID: PMC9382068.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382068/

Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis. 

Driedger M, Vachon ML, Wong A, Conway B, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld JJ, Lee SS, Cooper C. 

Can Liver J. 2021 Aug 9;4(3):283-291. doi: 10.3138/canlivj-2021-0003. PMID: 35992258; PMCID: PMC9202771.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202771/

Integrating Hepatitis C Care for Opioid Substitution Treatment Patients Attending General Practice: Feasibility, Clinical, and Cost-Effectiveness Analysis.

McCombe G, Swan D, Lambert JS, O'Connor E, Ward Z, Vickerman P, Avramovic G, Crowley D, Tinago W, Mafirakureva N, Cullen W. 

Interact J Med Res. 2022 Aug 23;11(2):e35300. doi: 10.2196/35300. PMID: 35998029; PMCID: PMC9449831.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449831/

Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.

Beer, L, Inglis, S, Malaguti, A, et al. 

J Viral Hepat. 2022; 29: 646- 653. doi: 10.1111/jvh.13701

https://onlinelibrary.wiley.com/doi/10.1111/jvh.13701

Personality dysfunction in opiate addicts on opioid substitution treatment and the risk of HCV infection. 

Skočibušić S, Zivlak-Radulović N, Hasanović M, Awad H, Karan-Križanac D, Mehić-Basara N, Rukavina T. 

Front Public Health. 2022 Sep 9;10:1009413. doi: 10.3389/fpubh.2022.1009413. PMID: 36159261; PMCID: PMC9507475.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507475/

Point-of-care hepatitis C reflex testing and treatment referral in methadone clinic settings in Hong Kong-a pilot study. 

Wong NS, Chan DP, Chan CP, Poon CM, Wong GL, Wong VW, Lee SS. 

IJID Reg. 2022 Aug 29;5:8-12. doi: 10.1016/j.ijregi.2022.08.007. PMID: 36119439; PMCID: PMC9471432.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471432/

Usability and acceptability of oral fluid hepatitis C self-testing among people who inject drugs in Coastal Kenya: a cross-sectional pilot study. 

Ivanova Reipold E, Fajardo E, Juma E, Bukusi D, Bermudez Aza E, Jamil MS, Johnson CC, Farquhar C, Easterbrook P, Monroe-Wise A. 

BMC Infect Dis. 2022 Sep 15;22(1):738. doi: 10.1186/s12879-022-07712-9. PMID: 36109704; PMCID: PMC9479404.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479404/

Hepatitis C antibody prevalence and behavioral correlates in people who inject drugs attending harm reduction services in Lisbon, Portugal. 

Curado A, Nogueira PJ, Virgolino A, Santa Maria J, Mendão L, Furtado C, Antunes F. 

Front Public Health. 2022 Aug 23;10:952909. doi: 10.3389/fpubh.2022.952909. PMID: 36081480; PMCID: PMC9445135.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445135/

Determining the feasibility for an overdose prevention line to support substance users who use alone. 

Ritchie K, Ghosh SM. 

Harm Reduct J. 2022 Aug 19;19(1):92. doi: 10.1186/s12954-022-00670-0. PMID: 35986328; PMCID: PMC9389809.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389809/

The Negative Impact of COVID-19 in HCV, HIV, and HPV Surveillance Programs During the Different Pandemic Waves. 

Romero-Hernández B, Martínez-García L, Rodríguez-Dominguez M, Martínez-Sanz J, Vélez-Díaz-Pallarés M, Pérez Mies B, Muriel A, Gea F, Pérez-Elías MJ, Galán JC. 

Front Public Health. 2022 Jul 22;10:880435. doi: 10.3389/fpubh.2022.880435. PMID: 35937266; PMCID: PMC9353175.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353175/

Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey. 

Kondili LA, Buti M, Riveiro-Barciela M, Maticic M, Negro F, Berg T, Craxì A. 

JHEP Rep. 2022 Sep;4(9):100531. doi: 10.1016/j.jhepr.2022.100531. Epub 2022 Jul 27. PMID: 35967191; PMCID: PMC9364666.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364666/

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study. 

Nikolaichuk M, Mocroft A, Wandeler G, Szlavik J, Gottfredsson M, Reikvam DH, Svedhem V, Elinav H, Laguno M, Mansinho K, Devitt E, Chkhartishvili N, Behrens G, Bogner J, Viard JP, Winston A, Benfield T, Leen C, Fursa O, Rockstroh J, Peters L; EuroSIDA study group. 

HIV Med. 2022 Aug 8. doi: 10.1111/hiv.13357. Epub ahead of print. PMID: 35934954.

https://onlinelibrary.wiley.com/doi/10.1111/hiv.13357

Hepatitis C virus risk among young people who inject drugs. 

Mateu-Gelabert P, Sabounchi NS, Guarino H, Ciervo C, Joseph K, Eckhardt BJ, Fong C, Kapadia SN, Huang TTK. 

Front Public Health. 2022 Jul 29;10:835836. doi: 10.3389/fpubh.2022.835836. PMID: 35968435; PMCID: PMC9372473.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372473/

Country versus pharmaceutical company interests for hepatitis C treatment. 

Lothan R, Gutman N, Yamin D. 

Health Care Manag Sci. 2022 Aug 24:1–25. doi: 10.1007/s10729-022-09607-2. Epub ahead of print. PMID: 36001218; PMCID: PMC9399601.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399601/

Evaluation der Akzeptanz der Gesetzesänderung in § 24 Infektionsschutzgesetz in niedrigschwelligen Einrichtungen der Aids- und Drogenhilfe - Evaluation of the Acceptance of the Amendment to § 24 of the German Infection Protection Act within Low Threshold Facilities 

Annabelle Cremer, York Zöllner, Armin Schafberger, Dirk Schäffer, Bernd Schulte

Suchttherapie 2022; 23(03): 141-149, DOI: 10.1055/a-1837-1106

Abstract

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1837-1106

Internationaler Leberkongress: Erste scharfe Waffe gegen Hepatitis D

Dtsch Arztebl 2022; 119(29-30): A-1306 / B-1095

Lenzen-Schulte, Martina

https://www.aerzteblatt.de/archiv/226249

#WorldHepatitisDay — EMCDDA practical resources to help European countries beat viral hepatitis 

Every year, on 28 July, the World Health Organization (WHO) and partners commemorate World Hepatitis Day to increase awareness and understanding of viral hepatitis and the diseases it causes. The focus of World Hepatitis Day this year is ‘Hep can't wait!', stressing the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for the people who need it (1). To mark the occasion, the EMCDDA is showcasing its online toolkit designed to help European countries beat viral hepatitis. The practical resources aim to support countries in promoting HCV testing and care for people who inject drugs (PWID) through drug services. (EMCDDA, Lissabon, 28.07.2022)

https://www.emcdda.europa.eu/news/2022/world-hepatitis-day-emcdda-practical-resources-help-european-countries-beat-viral-hepatitis_en

GBA. Gesundheitsuntersuchungs-Richtlinie: Einführung eines Screenings auf Hepatitis-B- und auf Hepatitis-C-Virusinfektion

Beschlussdatum: 20.11.2020, Inkrafttreten: 12.02.2021, Beschluss veröffentlicht: BAnz AT 11.02.2021 B1

https://www.g-ba.de/beschluesse/4566/